Shares of Pacira Biosciences Inc (NASDAQ:PCRX) have been assigned a consensus recommendation of “Hold” from the twenty research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $54.93.

Several research analysts have commented on PCRX shares. Stifel Nicolaus restated a “sell” rating and issued a $33.00 target price on shares of Pacira Biosciences in a research note on Friday, March 8th. Wedbush set a $91.00 target price on Pacira Biosciences and gave the stock a “buy” rating in a research note on Tuesday, January 29th. National Securities started coverage on Pacira Biosciences in a research note on Tuesday, February 12th. They issued a “sell” rating for the company. Mizuho downgraded Pacira Biosciences from a “neutral” rating to an “underperform” rating in a research note on Friday, February 1st. Finally, ValuEngine upgraded Pacira Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd.

NASDAQ PCRX traded down $0.11 during trading hours on Thursday, hitting $46.79. The company had a trading volume of 11,129 shares, compared to its average volume of 632,553. Pacira Biosciences has a 52 week low of $30.00 and a 52 week high of $55.00. The company has a quick ratio of 7.83, a current ratio of 8.62 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.94 billion, a P/E ratio of 161.20, a P/E/G ratio of 3.06 and a beta of 1.47.

Pacira Biosciences (NASDAQ:PCRX) last issued its earnings results on Thursday, May 2nd. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.02 by $0.20. Pacira Biosciences had a return on equity of 6.78% and a net margin of 2.10%. The business had revenue of $91.31 million during the quarter, compared to the consensus estimate of $92.13 million. During the same quarter last year, the company earned $0.02 EPS. The firm’s revenue was up 22.4% compared to the same quarter last year. Equities research analysts anticipate that Pacira Biosciences will post 0.67 EPS for the current year.

In other Pacira Biosciences news, Director Mark A. Kronenfeld purchased 1,700 shares of the stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $38.97 per share, with a total value of $66,249.00. Following the acquisition, the director now directly owns 9,277 shares in the company, valued at approximately $361,524.69. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. raised its holdings in shares of Pacira Biosciences by 71.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 170,439 shares of the company’s stock valued at $6,487,000 after acquiring an additional 71,150 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Pacira Biosciences by 6.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 26,242 shares of the company’s stock valued at $999,000 after acquiring an additional 1,525 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Pacira Biosciences by 0.5% during the 1st quarter. Northern Trust Corp now owns 522,403 shares of the company’s stock valued at $19,883,000 after buying an additional 2,466 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Pacira Biosciences during the 1st quarter valued at about $1,119,000. Finally, State of Wisconsin Investment Board raised its holdings in shares of Pacira Biosciences by 29.7% during the 1st quarter. State of Wisconsin Investment Board now owns 52,900 shares of the company’s stock valued at $2,013,000 after buying an additional 12,100 shares in the last quarter. 97.62% of the stock is currently owned by hedge funds and other institutional investors.

Pacira Biosciences Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes non-opioid pain management and regenerative health solutions to surgeons and anesthesiologists in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers.

Featured Story: Fundamental Analysis and Choosing Stocks

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.